Point Biopharma Global Inc Expected To Post A Loss Of 23 Cents A Share: Earnings Preview

POINT Biopharma Global

23/03/2022 12:39

* POINT Biopharma Global Inc  PNT.OQ   PNT.O  is expected
to report results on March 25.
    * ​Refinitiv's mean analyst estimate for POINT Biopharma
Global
Inc is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $17​, above​ its last closing price of $6.72. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.19       -0.19      -0.19     Met     -1.8
 Jun. 30 2021  -0.11       -0.11      -0.15     Missed  -36.4
                                                        ​
 ​​                                                     
                                                        ​
 This summary was machine generated March 23 at 12:39 GMT.  All
figures in US dollars  unless otherwise stated